Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Esperion's LDL-Cholesterol Drug To Follow PCSK9 Inhibitor Approval Pathway

This article was originally published in The Pink Sheet Daily

Executive Summary

Company says FDA confirmed that cardiovascular outcomes data will not be required for initial submission of ETC-1002 in patients with familial hypercholesterolemia and atherosclerotic CV disease; Esperion expects to start Phase III development by the end of 2015.

Advertisement

Related Content

Reading The Praluent Tea Leaves Ahead Of Repatha's Approval
PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data
Esperion Expects Phase IIb Data By Year-End On Cholesterol Candidate
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078818

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel